Gene-Engineered T cell Therapy for HPV-Associated Diseases

Scott Norberg, D.O. Assistant Research Physician
Experimental Transplantation and Immunotherapy Branch
Center for Cancer Research, NCI

Session Description:
HPV-Associated cancers account for 5% of all human cancers and approximately 44,000 new cases of cancer in the United States per year. They are difficult to treat, and metastatic disease is generally incurable. This session will provide an overview of the diseases, approved treatments and current clinical trials, including treatment that involves genetically engineered T-cells.

This activity has been submitted to the Ohio Nurses Association for approval to award contact hours. Ohio Nurses Association is accredited as an approver of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91)